GlassScriptPhysician profile
Sally Stipho
NPI 1467642215
$6,422.89
in general payments reported to CMS, 2019-2025
33 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $110 · 2021: $646 · 2022: $1,162 · 2023: $1,256 · 2024: $1,541 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,858.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,464.50 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,060.51 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $388.43 | 2021-2025 | Entyvio, Gattex |
| Pfizer INC. | $299.69 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.34 | 2019-2025 | Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $240.35 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $195.77 | 2019-2024 | Ocaliva |
| Celgene Corporation | $136.29 | 2022-2024 | Zeposia |
| Genzyme Corporation | $123.57 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $118.07 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $110.78 | 2019-2025 | |
| Madrigal Pharmaceuticals | $110.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $95.58 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $95.38 | 2023-2024 | Linzess |
| Ardelyx, INC. | $80.58 | 2024 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $77.38 | 2023-2024 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $62.67 | 2019-2022 | |
| Celltrion USA INC. | $58.64 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $56.71 | 2024 | Omvoh |
| Medtronic, INC. | $43.17 | 2024 | Pillcam |
| Merck Sharp & Dohme LLC | $41.09 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $39.22 | 2024 | Voquezna |
| Qol Medical, LLC | $36.94 | 2019-2021 | |
| Shionogi INC | $36.71 | 2019-2020 | |
| Redhill Biopharma INC. | $24.02 | 2021 | |
| Digestive Care, INC. | $22.96 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.71 | 2023 | Givlaari |
| Vivus LLC | $21.64 | 2024 | Qsymia |
| Allergan, INC. | $18.64 | 2019 | |
| Echosens North America, INC. | $17.61 | 2024 | Fibroscan |
| Axonics, INC. | $17.43 | 2021 | |
| Evoke Pharma, INC. | $15.57 | 2025 | |
| Endogastric Solutions, INC | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Stipho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.